AGP Executive Report
Last update: 3 hours agoDEA Rescheduling Fight: After 11 days of hearings, the DEA is arguing marijuana should move from Schedule I to Schedule III, while seven groups push back—so the “medical-use test” question could decide the outcome. Hemp THC Delay Push: The U.S. House is set to vote on delaying the federal hemp THC product ban (currently slated for November) to Dec. 11, giving lawmakers more time to craft rules. Medical Cannabis Access: A federally funded cancer study of 65 patients found symptom relief varies by THC/CBD mix, and researchers say insurance coverage is still a major barrier. Breastmilk & Cannabis: A new review says only two human studies exist on cannabis use and breastmilk nutrients/immune components, so diet and social factors may be driving differences. CBD for Pets: A vet warns dog CBD claims outpace research and FDA-style safety testing, urging caution with over-the-counter products. Work Absenteeism: A new study links medical cannabis access to fewer health-related missed workdays (about 7%), especially in physically demanding jobs. Regulatory/Trial Update: SciSparc’s NeuroThera partner says enrollment is progressing for a CBD-based autism trial (SCI-210). Enforcement Headlines: Police seized 22kg of suspected cannabis in Welland, and Barbados eradicated nearly 6,000 marijuana plants in St John.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
Pseudo-journalism: Pink-slime
